OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.
You may also be interested in...
Genentech's Lucentis Heads to FDA
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.
Genentech's Lucentis Heads to FDA
Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.
OSI Closes Lid On Eyetech Acquisition
Despite last-minute blink surrounding potential Macugen competition from Genentech’s Lucentis, OSI announces completion of the $935 mil. merger.